Connection

Michael Hallek to Tumor Suppressor Protein p53

Back to Details
This is a "connection" page, showing publications Michael Hallek has written about Tumor Suppressor Protein p53.
Michael Hallek
Connection Strength
1.140
Tumor Suppressor Protein p53
  1. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2017 Sep; 92(9):946-965.
    View in: PubMed
    Score: 0.571
  2. Exosome-dependent immune surveillance at the metastatic niche requires BAG6 and CBP/p300-dependent acetylation of p53. Theranostics. 2019; 9(21):6047-6062.
    View in: PubMed
    Score: 0.163
  3. Optimizing frontline therapy of CLL based on clinical and biological factors. Hematology Am Soc Hematol Educ Program. 2017 12 08; 2017(1):338-345.
    View in: PubMed
    Score: 0.145
  4. Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia. Nat Commun. 2017 07 28; 8(1):153.
    View in: PubMed
    Score: 0.142
  5. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood. 2009 Sep 24; 114(13):2589-97.
    View in: PubMed
    Score: 0.081
  6. Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. Clin Cancer Res. 2018 09 15; 24(18):4371-4379.
    View in: PubMed
    Score: 0.038
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.